Nabih Naim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nabih Naim has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Hampig Raphael Kourie
Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon
5 shared publications- Joseph Zouein
Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon
4 shared publications - Ali Shamseddine
Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
2 shared publications - Hampig Raphael Kourie
Saint Joseph University of Beirut
2 shared publications Kakil Rasul
Natonal Center for Cancer Care & Research in Hamad Medical Corporation
2 shared publicationsMervat Mahrous
Prince Sultan Military Medical City
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1933232
Optimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making
The approval of adjuvant nivolumab and pembrolizumab following radical cystectomy and more recently perioperative durvalumab-based strategies represents a significant therapeutic advance in muscle-invasive bladder cancer (MIBC). However, a question that has received limited systematic attention concerns the optimal timing of immunotherapy initiation after surgery. Current recommendations are derived entirely from the eligibility windows of pivotal clinical trials, most notably CheckMate 274, AMBASSADOR and NIAGARA, which mandated randomization within approximately 120 days of cystectomy. These operational thresholds were designed to ensure postoperative recovery and were not prospectively validated as biologically optimal. This review critically examines the biological rationale underpinning timing considerations, appraises what clinical trials have actually studied, draws cautious parallels with adjuvant chemotherapy literature, and discusses how circulating tumour DNA (ctDNA) and minimal residual disease (MRD) detection may eventually redefine timing decisions. We conclude that no validated therapeutic window currently exists, that available evidence supports initiation within the studied timeframe when clinically feasible, and that prospective timing analyzes constitute a major unmet need in MIBC research.
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1933232
Open AccessOptimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making
The approval of adjuvant nivolumab and pembrolizumab following radical cystectomy and more recently perioperative durvalumab-based strategies represents a significant therapeutic advance in muscle-invasive bladder cancer (MIBC). However, a question that has received limited systematic attention concerns the optimal timing of immunotherapy initiation after surgery. Current recommendations are derived entirely from the eligibility windows of pivotal clinical trials, most notably CheckMate 274, AMBASSADOR and NIAGARA, which mandated randomization within approximately 120 days of cystectomy. These operational thresholds were designed to ensure postoperative recovery and were not prospectively validated as biologically optimal. This review critically examines the biological rationale underpinning timing considerations, appraises what clinical trials have actually studied, draws cautious parallels with adjuvant chemotherapy literature, and discusses how circulating tumour DNA (ctDNA) and minimal residual disease (MRD) detection may eventually redefine timing decisions. We conclude that no validated therapeutic window currently exists, that available evidence supports initiation within the studied timeframe when clinically feasible, and that prospective timing analyzes constitute a major unmet need in MIBC research.
- Open Access
- 5 September 2026
- Published by Wolters Kluwer Health in Global Advances in Oncology and Hematology
- Vol. 1 (1) , 96-104
Durvalumab after Chemoradiotherapy for the Treatment of Patients with Stage III Non-Small Cell Lung Cancer: A Lebanese Real-World Study
Background: Based on the PACIFIC trial, durvalumab has been approved since 2018 as consolidation therapy for patients with unresectable stage III non-small cell lung cancer who have not progressed after chemoradiotherapy. Patients seen in everyday practice, however, are more heterogeneous than trial populations. Objectives: To assess the real-world use, effectiveness, and safety of durvalumab in patients with unresectable stage III non-small cell lung cancer in Lebanon. Materials and Methods: This phase IV, retrospective, multicenter study analyzed patient characteristics, progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs). Cox regression was used to assess the impact of age, sex, disease stage, histological subtype, programmed death ligand 1 (PD-L1) expression, type of prior chemoradiotherapy, and interval between chemoradiotherapy completion and durvalumab initiation on PFS. Results: Twenty-five patients were included, most with squamous histology (64%) and stage IIIB disease (92%). Twenty-three patients (92%) received prior concurrent chemoradiotherapy and two (8%) sequential chemoradiotherapy. PD-L1 expression was ≥1% in 40% of patients and <1% in 24%. Six patients (24%) experienced disease progression. Median PFS was 27.0 months (95% CI: 8.32–45.68), with PFS rates of 75.8% at 12 months and 66.3% at 24 months. The OS was 100% at 12 months and 87.5% at 24 months. None of the evaluated clinicopathological factors significantly influenced PFS. Four patients (16%) discontinued durvalumab because of AEs (grade 3 pneumonitis, psoriatic arthritis, grade 3 hepatotoxicity, and allergy). One patient with an adrenal oligometastasis underwent adrenalectomy and successfully resumed durvalumab. Conclusion: Our findings are consistent with those of the PACIFIC trial and other real-world studies, supporting the effectiveness and tolerability of consolidation durvalumab in clinical practice.
- 5 September 2026
- Published by Wolters Kluwer Health in Global Advances in Oncology and Hematology
- Vol. 1 (1) , 96-104
Open AccessDurvalumab after Chemoradiotherapy for the Treatment of Patients with Stage III Non-Small Cell Lung Cancer: A Lebanese Real-World Study
Background: Based on the PACIFIC trial, durvalumab has been approved since 2018 as consolidation therapy for patients with unresectable stage III non-small cell lung cancer who have not progressed after chemoradiotherapy. Patients seen in everyday practice, however, are more heterogeneous than trial populations. Objectives: To assess the real-world use, effectiveness, and safety of durvalumab in patients with unresectable stage III non-small cell lung cancer in Lebanon. Materials and Methods: This phase IV, retrospective, multicenter study analyzed patient characteristics, progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (AEs). Cox regression was used to assess the impact of age, sex, disease stage, histological subtype, programmed death ligand 1 (PD-L1) expression, type of prior chemoradiotherapy, and interval between chemoradiotherapy completion and durvalumab initiation on PFS. Results: Twenty-five patients were included, most with squamous histology (64%) and stage IIIB disease (92%). Twenty-three patients (92%) received prior concurrent chemoradiotherapy and two (8%) sequential chemoradiotherapy. PD-L1 expression was ≥1% in 40% of patients and <1% in 24%. Six patients (24%) experienced disease progression. Median PFS was 27.0 months (95% CI: 8.32–45.68), with PFS rates of 75.8% at 12 months and 66.3% at 24 months. The OS was 100% at 12 months and 87.5% at 24 months. None of the evaluated clinicopathological factors significantly influenced PFS. Four patients (16%) discontinued durvalumab because of AEs (grade 3 pneumonitis, psoriatic arthritis, grade 3 hepatotoxicity, and allergy). One patient with an adrenal oligometastasis underwent adrenalectomy and successfully resumed durvalumab. Conclusion: Our findings are consistent with those of the PACIFIC trial and other real-world studies, supporting the effectiveness and tolerability of consolidation durvalumab in clinical practice.
- 1 July 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (21) , 1451-1459
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer
Gastric cancer (GC) ranks as the fifth most prevalent cancer and the fourth deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, GC represents about 4.8% of cancer cases w...
- 1 July 2023
- Published by Taylor & Francis in Future Oncology
- Vol. 19 (21) , 1451-1459
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer
Gastric cancer (GC) ranks as the fifth most prevalent cancer and the fourth deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, GC represents about 4.8% of cancer cases w...
- 3 April 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (8) , 611-618
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?
Immunotherapy has improved the prognosis of many cancers, yet a large number of patients have demonstrated resistance to current immune checkpoint inhibitors. LAG-3 is an immune checkpoint expresse... Plain language summary Immunotherapy has increased survival rates for many cancer types; however, a large number of individuals experience resistance to this therapy and poor outcomes. Among the im... Tweetable abstract Coexpression of PD-1 and LAG-3 in solid or hematological cancers may be responsible for immunotherapy resistance; therefore, dual inhibition of PD-1 and LAG-3 may improve treatme...
- 3 April 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (8) , 611-618
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?
Immunotherapy has improved the prognosis of many cancers, yet a large number of patients have demonstrated resistance to current immune checkpoint inhibitors. LAG-3 is an immune checkpoint expresse... Plain language summary Immunotherapy has increased survival rates for many cancer types; however, a large number of individuals experience resistance to this therapy and poor outcomes. Among the im... Tweetable abstract Coexpression of PD-1 and LAG-3 in solid or hematological cancers may be responsible for immunotherapy resistance; therefore, dual inhibition of PD-1 and LAG-3 may improve treatme...
- 1 February 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (2) , 93-100
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?
Locoregional, as well as metastatic renal cell carcinoma, tends to relapse after nephrectomy or metastasectomy. Adjuvant therapy seems to be an effective strategy to reduce the risk of recurrence. ... Plain language summary Advanced and metastatic kidney cancer often tend to relapse after surgery. Treatment maintenance after surgery could be an effective strategy to reduce the risk of recurrence...
- 1 February 2023
- Published by Taylor & Francis in Immunotherapy
- Vol. 15 (2) , 93-100
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?
Locoregional, as well as metastatic renal cell carcinoma, tends to relapse after nephrectomy or metastasectomy. Adjuvant therapy seems to be an effective strategy to reduce the risk of recurrence. ... Plain language summary Advanced and metastatic kidney cancer often tend to relapse after surgery. Treatment maintenance after surgery could be an effective strategy to reduce the risk of recurrence...
- 6 July 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (24) , 2733-2744
The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer
Colorectal cancer (CRC) is ranked as the third most prevalent and the second deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, the number of CRC cases increased over th...
- 6 July 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (24) , 2733-2744
The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer
Colorectal cancer (CRC) is ranked as the third most prevalent and the second deadliest cancer worldwide. In the Middle East and North Africa (MENA) region, the number of CRC cases increased over th...
- 1 December 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 168, 103524
KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
- 1 December 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 168, 103524
KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
- 18 October 2021
- Published by Taylor & Francis in Personalized Medicine
- Vol. 18 (6) , 523-525
After Decades, RAS Mutation has Finally Become a Therapeutic Target
- 18 October 2021
- Published by Taylor & Francis in Personalized Medicine
- Vol. 18 (6) , 523-525
After Decades, RAS Mutation has Finally Become a Therapeutic Target